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Expansion of the Ub Code
Ubiquitin contains seven lysines; targeting different lysines or Met1 of Ub for chain formation allows the generation of a great variety of distinct Ub modifi cations. In addition to eight different homotypic chains, mixed and branched chains (chain elongation occurs on two lysines of a single Ub molecule) are also detected in cells. The assembly of Ub molecules into a poly-Ub chain is a highly coordinated process that gives rise to specifi c chain topologies. This is primarily achieved through the cooperation of specifi c E2/E3 enzyme pairs specialized for a certain type of linkage (Ye and Rape, 2009 ). Yet another layer of diversifi cation is achieved by acetylation of Lys6 or Lys48 or by phosphorylation of Ser65 of Ubiquitin (pS65-Ub) mediated by the mitochondrial kinase PINK1 (Herhaus and Dikic, 2015) . DUBs act as potent editors of polyUb chains, as their action allows the conversion of one chain type into another. Thus, the ubiquitination machinery facilitates the generation of a dynamic and extremely versatile post-translational code.
Reading of the Ub Code and Translation into Cellular Responses
The Ub tag added on a substrate represents a complex yet specifi c message that needs to be decoded by the cell. This is achieved through Ub receptors that are equipped with one or more Ub-binding domains (UBDs) (Husnjak and Dikic, 2012) . More than 20 different families of UBDs that bind different surface patches on Ub are known-the major one is surrounding Ile44. In their physiological intracellular milieu (often entailing multimerization of the Ub receptors), UBDs are able to sense the unique 3D conformation of differently linked Ub chains. In addition to their UBDs, Ub receptors contain domains such as interaction domains or enzymatic activities that relay the Ub signal to a specifi c cellular pathway. Distinct Ub-chain types are associated with distinct cellular pathways. For example, K48-linked chains lead to proteasomal degradation of the substrates, while M1-linked chains are implicated in the assembly of multimeric signaling complexes in the NF-kB pathway and Ub phosphorylated on S65 mediates the autophagic removal of damaged mitochondria (mitophagy). Ubiquitination has been implicated in virtually every cellular process and disturbances in "writing," "reading," or "erasing" the Ub code have been associated with a variety of diseases (Popovic et al., 2014) .
Pharmacological Exploitation of the Ub System
Targeting the Ub system at different checkpoints is possible thanks to the development of several pharmacological agents. Each one of the three enzymes (E1, E2, E3) that catalyze the ubiquitination cascade can be specifi cally inhibited by small-molecule inhibitors. Whereas attempts to target E1 and E2 enzymes had little benefi cial effects in pre-clinical trials (probably due to global effects on ubiquitination), inhibition of the enzymatic activity of E3 ligases that target tumor suppressor proteins like p53 for proteasomal degradation showed promising results. Further, a more specifi c intervention is achieved by small molecules that interfere with binding of the E3 ligase to a distinct substrate. For example, Nutlin-3 specifi cally blocks binding of the E3 ligase Mdm2 to the tumor suppressor p53, whereas other Mdm2 substrates are not affected (Zhao et al., 2015) . Small molecules that activate certain E3 ubiquitin ligases have also been developed. For instance, Smac mimetics bind to IAP (inhibitors of apoptosis) E3 ligases and trigger their auto-ubiquitination and degradation, therefore promoting death of tumor cells (Fulda and Vucic, 2012) . Another potent approach is to target DUBs that stabilize oncogenes. Several inhibitors of Usp7, whose substrate is Mdm2, are currently in pre-clinical trials (Pal et al., 2014) . The most successful drugs target the proteasome and lead to cell death of highly proliferating cells, such as cancer cells. The proteasomal inhibitor Velcade (Bortezomib) was the fi rst FDA-approved compound directed toward the ubiquitin system (Chen et al., 2011 ). An exciting novel approach uses bifunctional small molecules as tools to target specifi c proteins for removal from the cell. These small molecules serve as a bridge between a ubiquitously expressed E3 ubiquitin ligase such as CRL4 (CRBN) and a harmful protein by specifi cally binding to both of them, thereby enabling the labeling of the protein for proteasomal elimination. This principle was discovered to be the mechanism underlying the anti-tumorigenic effect of Thalidomide and other phthalimide immunomodulatory drugs (IMids) in the treatment of multiple myeloma (Fischer et al., 2014) . Theoretically, one can also envision molecules that target the Ub/UBD interface and therefore block the interpretation and translation of Ub signals. This would be a highly specifi c approach; however, despite remarkable progress in recent years, more structural and functional information is needed to fully understand how Ub receptors act to interpret the Ub code(s) in vivo.
